Wouter V. G.
- Country
- The Netherlands
- Department
- Pulmonary Diseases
Research Overview
- Phase 3 Randomized Placebo‑Controlled Trial of Adjuvant mRNA‑4157 (Intismeran) Plus Pembrolizumab Combination Therapy in Completely Resected High‑Risk Stage I NSCLC
- Therapeutic Drug Monitoring-Guided Versus Standard Dosing of Alectinib in ALK-Positive Non-Small Cell Lung Cancer Patients
- Evaluation of Extended Dosing Interval of Osimertinib in EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Data & Insights
Has run more than one trial at 7 of 62 partner sites.
Specializations
Advanced Lung Cancer Treatment
This investigator specializes in treating advanced Non-Small Cell Lung Cancer (NSCLC), with particular emphasis on cases involving specific genetic mutations and molecular markers.
- EGFR Exon 20 Insertion Mutations
- ALK-positive NSCLC
- HLA-A2 Positive Phenotype NSCLC
The investigator's work encompasses novel therapeutic approaches including targeted therapies and combination treatments for metastatic disease.
Precision Medicine Applications
The investigator focuses on developing personalized treatment strategies through various therapeutic modalities in lung cancer care.
- Targeted Molecular Therapies
- Therapeutic Drug Monitoring
- Combination Treatment Approaches
Their work includes investigating blood-level based dose adjustments and targeted therapeutic interventions.
Innovative Cancer Therapeutics
The investigator explores advanced therapeutic options for patients who have progressed through standard treatments.
- Therapeutic Cancer Vaccines
- Immunotherapy Approaches
- Alternative Treatment Strategies
Their research includes evaluating novel therapeutic options for patients who have experienced treatment failures with conventional approaches.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.